KA/EN
Register
Medicines reference
Search
Search
Product

Teknosul

Favourites

Trimethoprim/Sulfonamide · Teknovet

1 form: solution. In force in Georgia: 1 of 1 (veterinary register).

Forms and doses1 of 1 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Choose species and weight; the matching row will be highlighted.
Form Species Dose Frequency Georgia
200 mg/ml + 40 mg/ml, Solution · Cat Cat 30 mg/kg
30 mg/kg total active substance = 0.5 ml/4 kg (0.125 ml/kg) once daily by IM injection only for 3–5 days. Do not use IV or SC in cats. Use the 50 ml vial. If there is no important improvement within 3 days, review the diagnosis, culture/susceptibility and treatment plan.
 · once daily for 3–5 days		 once daily for 3–5 days Georgia Yes, veterinary
In force until 30 Nov 2026
Veterinary (National Food Agency)
In the register: ტექნოსული®
№ 002595, 002606
Verified on: 22 Oct 2026
200 mg/ml + 40 mg/ml, Solution · Dog Dog 30 mg/kg
30 mg/kg total active substance = 0.5 ml/4 kg (0.125 ml/kg) once daily by IM or slow IV injection for 3–5 days. Give IV slowly with monitoring. Use the 50 ml vial. If there is no important improvement within 3 days, review the diagnosis, culture/susceptibility and treatment plan.
 · once daily for 3–5 days		 once daily for 3–5 days Georgia Yes, veterinary
In force until 30 Nov 2026
Veterinary (National Food Agency)
In the register: ტექნოსული®
№ 002595, 002606
Verified on: 22 Oct 2026
Details: pack, label wording, sources, registration

Teknosul 200 mg/ml + 40 mg/ml, Solution

sulfamethoxazole + trimethoprim, solution for injection
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Label-concordant treatment of respiratory, gastrointestinal, urogenital and soft-tissue infections caused by bacteria susceptible to sulfamethoxazole/trimethoprim
6.2/10
Situational / acceptable
vetman assessment

Teknosul

200 mg/ml + 40 mg/ml, sulfamethoxazole + trimethoprim, solution for injection
Assessed clinical scopeDog · Label-concordant treatment of respiratory, gastrointestinal, urogenital and soft-tissue infections caused by bacteria susceptible to sulfamethoxazole/trimethoprim · IM,IV
Care settingVeterinary clinic or monitored parenteral treatment setting
vetman score 6.2/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, veterinary · № 002595, 002606 · Verified on 22 Oct 2026

A legitimate short-course injectable potentiated sulfonamide for a selected susceptible canine infection, not a broad empirical default. The exact dose and dog routes are clear, but culture, hydration, sulfonamide adverse-event screening and slow-IV discipline determine whether its benefit outweighs its risks.

Regulatory and scientific credibility6.5/10

Exact identity, strength, current manufacturer instruction and Georgian registration are verifiable, and internationally authorised same-class or same-formulation controls exist. However, the exact product lacks an accessible internationally recognised regulator SPC and independent exact-product outcome data.

Clinical efficacy6.5/10

Potentiated sulfonamides have guideline-supported roles in selected susceptible canine infections and direct canine cystitis trial evidence. Benefit remains culture- and syndrome-dependent; the broad label and mainly oral evidence do not prove equal efficacy of this injection across every listed infection.

Safety and tolerability5.5/10

A 3–5-day course limits cumulative toxicity, but dogs are unusually susceptible to KCS, hepatopathy, skin eruptions, blood dyscrasias, polyarthropathy and other idiosyncratic sulfonamide reactions. Hydration, organ and hypersensitivity boundaries are clinically material; slow IV use adds acute intolerance risk.

Clinical practicality6.5/10

Once-daily dosing for 3–5 days is workable in a clinic and IM administration is straightforward; slow IV requires venous access, monitoring and emergency readiness. The 50 ml companion-animal vial is much larger than many individual courses and can create wastage.

Full-course cost-effectiveness-

Current Georgian vial price and comparable weight-adjusted full-course costs were unavailable; price is excluded from the denominator.

Important safety and use flags

  • Hard stop: do not use with trimethoprim/sulfonamide hypersensitivity, severe hepatic or renal failure or a haematopoietic disorder. Stop and treat urgently for anaphylaxis, facial swelling, dyspnoea, collapse or a severe mucocutaneous/systemic reaction.
  • Species-specific route: dogs may receive IM or slow IV; cats receive IM only. Do not give IV to cats and avoid SC because the exact product warns of local reactions. Another 200/40 mg/ml product may use a different route and is not interchangeable.
  • Exact dose is 30 mg/kg total active = 0.5 ml/4 kg (0.125 ml/kg) once daily for 3–5 days. Use an accurately graduated syringe, especially in cats. If there is no important improvement within 3 days, review diagnosis and susceptibility rather than extending blindly.
  • Maintain adequate hydration. Dehydration and aciduria increase sulfonamide crystalluria and renal-injury risk; correct fluid deficits and monitor urine/renal status when clinically indicated.
  • Dogs have a comparatively high risk of potentiated-sulfonamide adverse effects: KCS, hepatopathy, fever, skin eruption, blood dyscrasia and polyarthropathy can be clinically important. For therapy beyond 7 days obtain baseline and repeat Schirmer testing; stop and reassess new ocular discharge or systemic signs.
  • Use cautiously in neonates, folate deficiency and patients at increased bleeding, renal or hepatic risk. Longer use can cause folate/haematopoietic toxicity, hepatotoxicity and hypothyroidism; the ordinary exact-product course is only 3–5 days.
  • Interaction review is required. PABA-related local anaesthetics and procaine penicillin can antagonise sulfonamides; historical exact-product information also flags methenamine, antacid, diuretic/furosemide and several compatibility concerns. Do not mix in one syringe or container without verified compatibility.
  • Reproductive safety is incomplete. Historical exact-product information reports no observed therapeutic-dose harm in pregnant dogs, but class placental transfer and high-dose laboratory-animal teratogenicity remain; no adequate exact feline pregnancy/lactation dataset was identified. Use only after explicit benefit–risk assessment.
  • Antimicrobial stewardship: treat a proven or strongly suspected susceptible bacterial infection, obtain culture for recurrent, complicated, deep or non-responsive disease and reassess when results return. Do not treat viral disease itself, sterile inflammation, asymptomatic bacteriuria or Enterococcus on a broad label alone.
  • Clinic handling: use aseptic technique and the 50 ml dog/cat vial. For dog IV use, administer slowly with monitoring and emergency readiness; interrupt at the first sign of intolerance. Respect the 50-puncture limit for 50/100 ml vials and current storage/in-use instructions.
Assessment sources
  1. Teknovet Teknosul exact2026
  2. Teknovet catalogue2022
  3. NFA Teknosul exact2026
  4. ISCAID UTI2019
  5. Canine TMP-SMX RCT2014
  6. ISCAID canine pyoderma guideline2025
  7. EMA AMEG 20252025
  8. UPD Vanasulf control2026
  9. VMD Diatrim control2024
  10. FDA Primor control2017
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Label-concordant treatment of respiratory, gastrointestinal, urogenital and soft-tissue infections caused by bacteria susceptible to sulfamethoxazole/trimethoprim
6.1/10
Situational / acceptable
vetman assessment

Teknosul

200 mg/ml + 40 mg/ml, sulfamethoxazole + trimethoprim, solution for injection
Assessed clinical scopeCat · Label-concordant treatment of respiratory, gastrointestinal, urogenital and soft-tissue infections caused by bacteria susceptible to sulfamethoxazole/trimethoprim · Intramuscular
Care settingVeterinary clinic or monitored parenteral treatment setting
vetman score 6.1/10 Situational / acceptable
Evidence confidence: Low Georgia: Yes, veterinary · № 002595, 002606 · Verified on 22 Oct 2026

A locally registered IM option for a selected susceptible feline bacterial infection, with a clear exact dose but limited direct feline outcome evidence. It is reasonable only when the diagnosis, susceptibility, hydration and organ status justify repeated IM treatment.

Regulatory and scientific credibility6.5/10

Exact identity, strength, current manufacturer instruction and Georgian registration are verifiable, and internationally authorised same-class or same-formulation controls exist. However, the exact product lacks an accessible internationally recognised regulator SPC and independent exact-product outcome data.

Clinical efficacy6.0/10

The active class has a recognised role in selected susceptible feline infections and valid dog/cat injectable analogues exist, but direct feline clinical outcomes for this exact product and route were not identified. The broad label therefore rests mainly on class evidence and susceptibility.

Safety and tolerability6.0/10

The labelled course is short and IM-only use avoids IV intolerance, but hypersensitivity, crystalluria/renal injury, folate-haematopoietic toxicity, liver disease and local reaction remain meaningful. Exact feline reproductive and outcome safety data are sparse.

Clinical practicality6.0/10

Once-daily IM treatment for 3–5 days is feasible in clinic, but repeated feline restraint and injection are material burdens. The small 0.125 ml/kg volume requires an accurately graduated syringe, while the required 50 ml vial creates substantial single-patient wastage.

Full-course cost-effectiveness-

Current Georgian vial price and comparable weight-adjusted full-course costs were unavailable; price is excluded from the denominator.

Important safety and use flags

  • Hard stop: do not use with trimethoprim/sulfonamide hypersensitivity, severe hepatic or renal failure or a haematopoietic disorder. Stop and treat urgently for anaphylaxis, facial swelling, dyspnoea, collapse or a severe mucocutaneous/systemic reaction.
  • Species-specific route: dogs may receive IM or slow IV; cats receive IM only. Do not give IV to cats and avoid SC because the exact product warns of local reactions. Another 200/40 mg/ml product may use a different route and is not interchangeable.
  • Exact dose is 30 mg/kg total active = 0.5 ml/4 kg (0.125 ml/kg) once daily for 3–5 days. Use an accurately graduated syringe, especially in cats. If there is no important improvement within 3 days, review diagnosis and susceptibility rather than extending blindly.
  • Maintain adequate hydration. Dehydration and aciduria increase sulfonamide crystalluria and renal-injury risk; correct fluid deficits and monitor urine/renal status when clinically indicated.
  • Direct feline outcome safety evidence for exact Teknosul is limited. Monitor injection sites, appetite, vomiting, fever, skin/mucosal change, urine output and haematological or hepatic signs; stop and reassess a suspected hypersensitivity or organ reaction.
  • Use cautiously in neonates, folate deficiency and patients at increased bleeding, renal or hepatic risk. Longer use can cause folate/haematopoietic toxicity, hepatotoxicity and hypothyroidism; the ordinary exact-product course is only 3–5 days.
  • Interaction review is required. PABA-related local anaesthetics and procaine penicillin can antagonise sulfonamides; historical exact-product information also flags methenamine, antacid, diuretic/furosemide and several compatibility concerns. Do not mix in one syringe or container without verified compatibility.
  • Reproductive safety is incomplete. Historical exact-product information reports no observed therapeutic-dose harm in pregnant dogs, but class placental transfer and high-dose laboratory-animal teratogenicity remain; no adequate exact feline pregnancy/lactation dataset was identified. Use only after explicit benefit–risk assessment.
  • Antimicrobial stewardship: treat a proven or strongly suspected susceptible bacterial infection, obtain culture for recurrent, complicated, deep or non-responsive disease and reassess when results return. Do not treat viral disease itself, sterile inflammation, asymptomatic bacteriuria or Enterococcus on a broad label alone.
  • Clinic handling: use aseptic technique and the 50 ml dog/cat vial. For dog IV use, administer slowly with monitoring and emergency readiness; interrupt at the first sign of intolerance. Respect the 50-puncture limit for 50/100 ml vials and current storage/in-use instructions.
Assessment sources
  1. Teknovet Teknosul exact2026
  2. Teknovet catalogue2022
  3. NFA Teknosul exact2026
  4. ISCAID UTI2019
  5. EMA AMEG 20252025
  6. UPD Vanasulf control2026
  7. VMD Diatrim control2024
  8. FDA Primor control2017
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Trimethoprim/Sulfonamide240 mg/ml
Formulation Type
Solution
Administration route
Intramuscular, Intravenous
Manufacturer
Teknovet · Türkiye
Registration
Georgia Yes, veterinary
In force until 30 Nov 2026
Veterinary (National Food Agency)
In the register: ტექნოსული®
№ 002595, 002606
Verified on: 22 Oct 2026
 EU No
Verified on: 22 Oct 2026
 UK No
Verified on: 22 Oct 2026
 US No
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified Dogs: 0.5 ml/4 kg (0.125 ml/kg; 30 mg/kg total active) IM or slow IV once daily for 3–5 days. Cats: the same weight dose IM only once daily for 3–5 days; do not use IV or SC. Use the 50 ml vial for companion animals. Review diagnosis and susceptibility if there is no important improvement within 3 days.
DoseSpeciesWeightRouteFrequencySource
30 mg/kg
30 mg/kg total active substance = 0.5 ml/4 kg (0.125 ml/kg) once daily by IM injection only for 3–5 days. Do not use IV or SC in cats. Use the 50 ml vial. If there is no important improvement within 3 days, review the diagnosis, culture/susceptibility and treatment plan.
 Cat Any weight Intramuscular once daily for 3–5 days
Teknovet Teknosul exact
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
Teknosul 200 mg/ml + 40 mg/ml solution for injection - current exact product information
Teknovet, 2026
30 mg/kg
30 mg/kg total active substance = 0.5 ml/4 kg (0.125 ml/kg) once daily by IM or slow IV injection for 3–5 days. Give IV slowly with monitoring. Use the 50 ml vial. If there is no important improvement within 3 days, review the diagnosis, culture/susceptibility and treatment plan.
 Dog Any weight IM,IV once daily for 3–5 days
Teknovet Teknosul exact
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
Teknosul 200 mg/ml + 40 mg/ml solution for injection - current exact product information
Teknovet, 2026

Known Contraindications

  • Critical
    Do not use in cases of hypersensitivity to the active substances (or any other sulfonamide)
    Sources: VMD SPC · VMD
  • Critical
    Do not use in case of severe liver or kidney insufficiency or blood dyscrasia. Do not use in animals with severe liver or renal damage
    Sources: VMD SPC · VMD
  • Critical
    Do not use in case of severe liver or kidney insufficiency or blood dyscrasia.
    Sources: VMD SPC · VMD
  • Critical
    Do not use in case of... blood dyscrasia
    Sources: VMD SPC · VMD
  • Critical
    Do not use trimethoprim/sulfonamide combinations when water intake is reduced or body-fluid loss is present. Maintain adequate hydration during treatment to reduce crystalluria and renal injury.
  • Warning
    Safety during pregnancy and lactation has not been established. Long-term exposure produced fetotoxic effects in laboratory mice; use only after an individual benefit-risk assessment.
  • Warning
    Safety during lactation has not been established. Use only after an individual benefit-risk assessment.
  • Warning (Dog)
    Trimethoprim/sulfonamide treatment can cause keratoconjunctivitis sicca in dogs, particularly during courses longer than 7 days. Perform a baseline Schirmer tear test, repeat it periodically, and stop promptly if tear production falls or ocular discharge develops.
    Sources: ISCAID
  • Warning (Dog)
    Dogs are particularly susceptible to idiosyncratic sulfonamide reactions, including fever, blood dyscrasias, polyarthropathy, skin eruptions, acute hepatopathy, and proteinuria. A breed-associated risk has been proposed in Dobermans, but the evidence is uncertain.
    Sources: ISCAID
  • Caution
    During prolonged trimethoprim/sulfonamide treatment, perform periodic haematology and monitor thyroid function when clinically indicated. High doses can cause reversible hypothyroidism in dogs.
    Sources: ISCAID · MSD Vet Manual

Known Drug Interactions

  • Minor warning Trimethoprim/Sulfonamide + Ganciclovir
    Although systemic exposure after ophthalmic ganciclovir is low, an interaction with trimethoprim/sulfonamide combinations cannot be excluded; additive bone-marrow toxicity is possible.
    Recommendation: Systemic absorption from the eye gel is low; perform haematology monitoring during prolonged combination therapy.
    Sources: Virgan SmPC
  • Minor warning Trimethoprim/Sulfonamide + Procaine Benzylpenicillin
    Procaine (in procaine benzylpenicillin) is an ester of para-aminobenzoic acid (PABA). Like other PABA-ester local anaesthetics such as tetracaine, it can reduce the effect of potentiated sulfonamides, at least locally.
    Recommendation: Account for a reduced sulfonamide effect during concomitant administration.
    Sources: MSD Vet Manual
  • Minor warning Amoxicillin + Trimethoprim/Sulfonamide
    Concurrent use of bactericidal beta-lactam antibiotics and bacteriostatic antimicrobials such as sulfonamides is generally not recommended because their effects may be antagonistic.
    Recommendation: Avoid concomitant administration.

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (59 more) Hide additional products

Same therapeutic group 59

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗